

## I. AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions and listings.

### Listing of Claims:

Claim 1 (canceled).

Claim 2 (currently amended) A method of increasing angiogenesis, comprising administering to a patient in need of increased angiogenesis an angiogenesis stimulating amount of a pharmaceutical composition containing a peptide or pharmaceutically acceptable salt thereof comprising the amino acid sequence

LLGDFFRKSKKEKIGKEFKRIVQRIKDFLRNLVPRTES (LL-37) (SEQ ID NO: 1) and a pharmaceutically acceptable carrier.

Claims 3-20 (canceled).

Claim 21 (previously presented) The method of claim 2, wherein the peptide consists of SEQ ID NO: 1.

Claim 22 (previously presented) A method of increasing angiogenesis, comprising administering to a patient a LL-37-receptor agonist in a pharmaceutically acceptable carrier in an amount sufficient to stimulate angiogenesis.

Claim 23 (previously presented) The method of claim 22, wherein the LL-37-receptor agonist comprises SEQ ID NO: 1.

Claim 24 (previously presented) The method of claim 22, wherein the LL-37-receptor agonist consists of SEQ ID NO: 1.

Claim 25 (previously presented) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating derivative of SEQ ID NO: 1.

Claim 26 (previously presented) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating peptidomimetic of SEQ ID NO: 1.

Claim 27 (previously presented) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating mutant of SEQ ID NO: 1.

Claim 28 (previously presented) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating fragment of SEQ ID NO: 1.

Claim 29 (withdrawn) A method of modulating angiogenesis, comprising administering to a patient in need of modulating angiogenesis a formyl peptide receptor-like 1 (FPRL1) agonist in a pharmaceutically acceptable carrier in an amount sufficient to stimulate angiogenesis or administering to a patient a FPRL1 antagonist in a pharmaceutically acceptable carrier in an amount sufficient to decrease angiogenesis.

Claim 30 (withdrawn) The method of claim 29, wherein the FPRL1 agonist comprises SEQ ID NO: 1.

Claim 31 (withdrawn) The method of claim 29, wherein the FPRL1 agonist consists of SEQ ID NO: 1.

Claim 32 (withdrawn) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating derivative of SEQ ID NO: 1.

Claim 33 (withdrawn) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating peptidomimetic of SEQ ID NO: 1.

Claim 34 (withdrawn) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating mutant of SEQ ID NO: 1.

Claim 35 (withdrawn) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating fragment of SEQ ID NO: 1.

Claim 36 (withdrawn) The method of claim 29, wherein the FPRL1 antagonist comprises an antibody that specifically binds to a peptide having SEQ ID NO: 1.

Claim 37 (withdrawn) The method of claim 29, wherein the FPRL1 antagonist comprises an anti-FPRL1 antibody.

Claim 38 (withdrawn) The method of claim 29, wherein the FPRL1 antagonist comprises a non-angiogenesis-stimulating mutant of SEQ ID NO: 1.

Claim 39 (withdrawn) The method of claim 29, wherein the FPRL1 antagonist comprises a soluble form of FPRL1.